Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Clinical trial NCT02282020 · COMPLETED

Trial details

NCT number: NCT02282020
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Start date: 2015-02-06
Primary completion: 2018-10-10
Enrollment: 266

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.